Drug Trial Radar · NCT03093909
Study of Aerosol Gemcitabine in Patients With Solid Tumors and Pulmonary Metastases
Last checked: Nov 20, 2026Latest source record: Nov 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
44
Planned (sponsor's estimate)
Start
Nov 22, 2017
Primary completion
Nov 30, 2027
Study completion Nov 30, 2027
Sponsor
- Lead sponsor
- M.D. Anderson Cancer CenterAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- James B. and Lois R. Archer Charitable Foundation; Gateway for Cancer Research
- First posted
- Mar 28, 2017
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 12 years, up to 50 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Any time the words "you," "your," "I," or "me" appear, it is meant to apply to the potential participant. The goal of this clinical research study is to find the highest tolerable dose of gemcitabine that can be given by inhalation (breathing it as a mist) to patients with solid tumors that have spread to the lungs from other parts of the body. The safety and side effects of this drug will also be studied. This is an investigational study. Gemcitabine is FDA approved and commercially available for the treatment of pancreatic and lung cancer, and other solid tumors. Its administration by inhalation is investigational. The study doctor can explain how the study drug is designed to work. Up to 44 participants will be enrolled in this study. All will take part at MD Anderson.
Conditions
- Malignant Neoplasm of Bone and Articular Cartilage
- Malignant Neoplasms of Female Genital Organs
- Malignant Neoplasms of Independent (Primary) Multiple Sites
- Malignant Neoplasms of Lip Oral Cavity and Pharynx
- Malignant Neoplasm of Male Genital Organs
- Malignant Neoplasms of Mesothelial and Soft Tissue
- Malignant Neoplasm of Respiratory and Intrathoracic Organ Carcinoma
- Malignant Neoplasms of Thyroid and Other Endocrine Glands
- Malignant Neoplasms of Urinary Tract
- Melanoma and Other Malignant Neoplasms of Skin
Interventions
GemcitabineDrug
Nebulized dose of aerosol GCB twice a week continuously (escalating treatment dose schema, starting at 0.75 mg/kg to 3.0 mg/kg). Participants receive a pre-determined volume of nebulized solution, according to the dose level and weight of the participant, with each aerosol GCB administration. One cycle is 4 weeks in duration.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Maximum Tolerated Dose (MTD) Recommended for Phase 2 Dose of Aerosol Gemcitabine (GCB)Time frame: 4 weeks
- Toxicities of Aerosol Gemcitabine (GCB)Time frame: Reviewed with each 4 week cycle, up to 24 weeks for six dose levels
Locations
1 site in 1 country. Site status is shown where the registry gives one.
The University of Texas MD Anderson Cancer Center
Houston, Texas · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.